ATE411808T1 - Fettbindende polymere - Google Patents

Fettbindende polymere

Info

Publication number
ATE411808T1
ATE411808T1 AT02744787T AT02744787T ATE411808T1 AT E411808 T1 ATE411808 T1 AT E411808T1 AT 02744787 T AT02744787 T AT 02744787T AT 02744787 T AT02744787 T AT 02744787T AT E411808 T1 ATE411808 T1 AT E411808T1
Authority
AT
Austria
Prior art keywords
binding polymers
fat
subjects
lipase inhibitors
fat binding
Prior art date
Application number
AT02744787T
Other languages
English (en)
Inventor
Stephen Holmes-Farley
Original Assignee
Genzyme Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Genzyme Corp filed Critical Genzyme Corp
Application granted granted Critical
Publication of ATE411808T1 publication Critical patent/ATE411808T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/74—Synthetic polymeric materials
    • A61K31/785—Polymers containing nitrogen
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/74—Synthetic polymeric materials
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives

Landscapes

  • Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Epidemiology (AREA)
  • Cardiology (AREA)
  • Reproductive Health (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Endocrinology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Gynecology & Obstetrics (AREA)
  • Emergency Medicine (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Urology & Nephrology (AREA)
  • Immunology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Rheumatology (AREA)
  • Pregnancy & Childbirth (AREA)
  • Pulmonology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Addition Polymer Or Copolymer, Post-Treatments, Or Chemical Modifications (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Polyoxymethylene Polymers And Polymers With Carbon-To-Carbon Bonds (AREA)
  • Adhesives Or Adhesive Processes (AREA)
AT02744787T 2001-06-29 2002-07-01 Fettbindende polymere ATE411808T1 (de)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US30222101P 2001-06-29 2001-06-29
US30208101P 2001-06-29 2001-06-29
US35946702P 2002-02-22 2002-02-22
US35947402P 2002-02-22 2002-02-22
US35947302P 2002-02-22 2002-02-22

Publications (1)

Publication Number Publication Date
ATE411808T1 true ATE411808T1 (de) 2008-11-15

Family

ID=27540878

Family Applications (1)

Application Number Title Priority Date Filing Date
AT02744787T ATE411808T1 (de) 2001-06-29 2002-07-01 Fettbindende polymere

Country Status (8)

Country Link
US (2) US7049345B2 (de)
EP (1) EP1404349B1 (de)
JP (1) JP2005502615A (de)
AT (1) ATE411808T1 (de)
AU (1) AU2002346034B2 (de)
CA (1) CA2490219A1 (de)
DE (1) DE60229523D1 (de)
WO (1) WO2003002130A1 (de)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20060134062A1 (en) * 2002-11-19 2006-06-22 Huval Chad C Polymeric boronic acid derivatives as lipase inhibitors
US20080107748A1 (en) * 2006-11-06 2008-05-08 Krishan Kumar Singal Microcapsules for removing and absorbing a chemical from a mixture
US9044235B2 (en) 2008-02-18 2015-06-02 Covidien Lp Magnetic clip for implant deployment device
US9301826B2 (en) 2008-02-18 2016-04-05 Covidien Lp Lock bar spring and clip for implant deployment device
US8758373B2 (en) 2008-02-18 2014-06-24 Covidien Lp Means and method for reversibly connecting a patch to a patch deployment device
US9833240B2 (en) 2008-02-18 2017-12-05 Covidien Lp Lock bar spring and clip for implant deployment device
US8317808B2 (en) 2008-02-18 2012-11-27 Covidien Lp Device and method for rolling and inserting a prosthetic patch into a body cavity
WO2009104182A2 (en) 2008-02-18 2009-08-27 Polytouch Medical Ltd A device and method for deploying and attaching a patch to a biological tissue
US9398944B2 (en) 2008-02-18 2016-07-26 Covidien Lp Lock bar spring and clip for implant deployment device
US8808314B2 (en) 2008-02-18 2014-08-19 Covidien Lp Device and method for deploying and attaching an implant to a biological tissue
US9034002B2 (en) 2008-02-18 2015-05-19 Covidien Lp Lock bar spring and clip for implant deployment device
US9393093B2 (en) 2008-02-18 2016-07-19 Covidien Lp Clip for implant deployment device
US9393002B2 (en) 2008-02-18 2016-07-19 Covidien Lp Clip for implant deployment device
EP2792307B1 (de) 2008-10-20 2017-10-04 Covidien LP Vorrichtung zur Anbringung eines Pflasters auf einem biologischen Gewebe
AU2010286117B9 (en) 2009-08-17 2014-07-10 Covidien Lp Articulating patch deployment device and method of use
US9999424B2 (en) 2009-08-17 2018-06-19 Covidien Lp Means and method for reversibly connecting an implant to a deployment device
CN104955446B (zh) * 2012-12-21 2017-08-22 财团法人卫生研究院 用于吸收油脂的中孔洞硅奈米粒子

Family Cites Families (43)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NL7017227A (de) 1969-12-27 1971-06-29
US3923972A (en) 1971-10-12 1975-12-02 Monsanto Co Method of lowering blood cholesterol level
US4211765A (en) 1971-10-12 1980-07-08 Monsanto Company Method for controlling obesity
IT1052819B (it) 1975-12-12 1981-07-20 Fargal Pharmasint Lab Biochim Preparato inibitore dell assorbimento dei lipidi a base di dietilamminoetildestrano
US4265879A (en) 1977-09-13 1981-05-05 Monsanto Company Method for controlling blood triglycerides
US4302450A (en) 1979-01-15 1981-11-24 Hoffmann-La Roche Inc. Polyether ionophores as antiobesity and hypotriglyceridemic agents
US4218443A (en) 1979-01-15 1980-08-19 Hoffmann-La Roche Inc. Polyether ionophores as antiobesity and hypotriglyceridemic agents
CA1213397A (en) 1980-10-20 1986-10-28 Judith L. Page Weight control with alkyl styrene polymers
US4432968A (en) 1980-10-20 1984-02-21 The Dow Chemical Company Weight control with fat imbibing polymers
IT1133979B (it) 1980-10-22 1986-07-24 Ponteggi Est Spa Testata di ancoraggio per trefoli o cavi atti a mettere in tensione strutture metalliche o in calcestruzzo
CA1247547A (en) 1983-06-22 1988-12-28 Paul Hadvary Leucine derivatives
US5597810A (en) 1984-12-27 1997-01-28 Hoffman; Allan S. Method for reducing absorption of undesired lipids in the gastrointestinal tract
US5200183A (en) 1987-11-19 1993-04-06 Oklahoma Medical Research Foundation Recombinant bile salt activated lipases
JPH02503205A (ja) 1988-02-12 1990-10-04 ドゥ　ツァープフェル，ブリギット 医用及びパラメディカル用の架橋親水性コポリマー
US5089163A (en) 1989-01-30 1992-02-18 Lever Brothers Company, Division Of Conopco, Inc. Enzymatic liquid detergent composition
US4959179A (en) 1989-01-30 1990-09-25 Lever Brothers Company Stabilized enzymes liquid detergent composition containing lipase and protease
US5063210A (en) 1989-04-20 1991-11-05 Lange Iii Louis G Use of sulfated polysaccharides to decrease cholesterol and fatty acid absorption
US5484777A (en) 1989-04-20 1996-01-16 Lange, Iii; Louis G. Pancreatic cholesterol esterase inhibitor
US5308766A (en) 1989-08-29 1994-05-03 The Regents Of The University Of California Hydrolytic enzyme inhibitors/inactivators and methods for using same
WO1991003544A1 (en) 1989-08-29 1991-03-21 The Regents Of The University Of California Novel hydrolytic enzyme inhibitors and substrates and assays, methods and kits embodying same
US5260310A (en) 1990-02-26 1993-11-09 Hoffmann-La Roche Inc. Oxetanone compounds and pharmaceutical compositions containing them
US5137716A (en) 1990-11-15 1992-08-11 Weisenfeld Michael S Method of reducing weight in mammals
JP2709658B2 (ja) 1991-04-30 1998-02-04 第一工業製薬株式会社 ロジン系エマルジョンサイズ剤用乳化分散剤及びサイズ剤
EP0622078B1 (de) 1992-01-14 1999-09-01 Hisamitsu Pharmaceutical Co., Inc. Cholesterinspiegelsenkendes mittel
JP2667351B2 (ja) 1992-03-24 1997-10-27 麒麟麦酒株式会社 食餌脂質消化吸収阻害剤および飲食品
DK0563731T3 (da) 1992-03-28 1996-03-18 Hoechst Ag Lægemidler indeholdende polyhydromethylenderivater, fremgangsmåde til deres fremstilling og deres anvendelse
JP3507523B2 (ja) 1993-05-12 2004-03-15 積水化学工業株式会社 糖質吸収抑制剤
US5618530A (en) 1994-06-10 1997-04-08 Geltex Pharmaceuticals, Inc. Hydrophobic amine polymer sequestrant and method of cholesterol depletion
US5900475A (en) 1994-06-10 1999-05-04 Geltex Pharmaceuticals, Inc. Hydrophobic sequestrant for cholesterol depletion
US5703188A (en) 1993-06-02 1997-12-30 Geltex Pharmaceuticals, Inc. Process for removing bile salts from a patient and compositions therefor
US5607669A (en) 1994-06-10 1997-03-04 Geltex Pharmaceuticals, Inc. Amine polymer sequestrant and method of cholesterol depletion
US5624963A (en) 1993-06-02 1997-04-29 Geltex Pharmaceuticals, Inc. Process for removing bile salts from a patient and compositions therefor
US5569452A (en) 1993-08-31 1996-10-29 Tsrl, Inc. Pharmaceutical formulation having enhanced bile acid binding affinity
US5414068A (en) 1994-01-24 1995-05-09 Rohm And Haas Company Crosslinked anion exchange particles and method for producing the particles
TW474813B (en) 1994-06-10 2002-02-01 Geltex Pharma Inc Alkylated composition for removing bile salts from a patient
US5474993A (en) 1994-06-14 1995-12-12 Sterling Winthrop, Inc. Lactam inhibitors of cholesterol esterase
JPH0859458A (ja) 1994-08-25 1996-03-05 Zeria Pharmaceut Co Ltd インダン誘導体を含有する高脂血症治療剤
US5900233A (en) 1997-10-16 1999-05-04 Day; Charles E. Epichlorohydrin and 1-(3-aminopropyl) imidazole copolymer and its use in treating irritable bowel syndrome
US6299868B1 (en) 1999-07-14 2001-10-09 Geltex Pharmaceuticals, Inc. Fat-binding polymers
US6264937B1 (en) 1998-01-09 2001-07-24 Geltex Pharmaceuticals, Inc. Fat-binding polymers
TR200100472T2 (tr) 1998-08-14 2001-07-23 F.Hoffmann-La Roche Ag Lipaz inhibitörleri ile sitozan içeren farmasötik bileşimler
CN1170534C (zh) 1998-08-14 2004-10-13 霍夫曼-拉罗奇有限公司 含有脂酶抑制剂的药物组合物
IL147361A0 (en) 1999-07-14 2002-08-14 Geltex Pharma Inc Fat-binding polymers, optionally combined with lipase inhibitors

Also Published As

Publication number Publication date
EP1404349A1 (de) 2004-04-07
JP2005502615A (ja) 2005-01-27
AU2002346034B2 (en) 2005-10-13
US20060127353A1 (en) 2006-06-15
US20030039626A1 (en) 2003-02-27
DE60229523D1 (de) 2008-12-04
US7049345B2 (en) 2006-05-23
EP1404349B1 (de) 2008-10-22
WO2003002130A1 (en) 2003-01-09
CA2490219A1 (en) 2003-01-09

Similar Documents

Publication Publication Date Title
ATE411808T1 (de) Fettbindende polymere
DK1411951T4 (da) Enteralt præparat til forebyggelse og/eller behandling af sepsis
EP2537524A3 (de) Behandlung von T-Zell-vermittelten Krankheiten
YU37304A (sh) Specifični agensi koji vezuju humani angiopoetin-2
EP2453024A3 (de) Differenziell exprimierte Gene und Leitungsbahnen bei bipolarer Störung und/oder schwerer depressiver Erkrankung
WO2004022580A3 (en) Bh3 peptides and method of use thereof
WO2001068112A3 (en) Effects of glucagon-like peptide-1 (7-36) on antro-pyloro-duodenal motility
PT1171465E (pt) Analogos de petido inibidor gastrico e sua utilizacao para o tratamento de diabetes
WO2006066008A3 (en) Device and methods for identifying and treating aspirin non-responsive patients
WO2001031580A3 (en) Methods and devices for identifying patterns in biological systems
WO2002099055A3 (en) Cips as modifiers of the p53 pathway and method of use
MX2008002114A (es) Inhibidores de n-(arilamino)-sulfonamida de mek.
NZ263344A (en) Human bactericidal/permeability increasing (bpi) protein functional domain peptides and their use
EP2402372A3 (de) Therapeutischer Wirkstoff
ATE540129T1 (de) Target zur therapie kognitiver behinderungen
NO20050569D0 (no) Fremgangsmate for behandling av alvorlig hjertesvikt og medikament for dette
EP1831266A4 (de) Vernetzte aminpolymere
ATE419516T1 (de) Monoklonale antikörper und zelloberflächenantigene zum nachweis und zur behandlung von kleinzelligem lungenkrebs (sclc)
WO2003079020A3 (en) Methods and compositions for the identification, assessment, and therapy of small cell lung cancer
NO20055309D0 (no) Slurp-1 samrnensetninger og fremgangsmater for anvendelse derav
ME00578A (en) Use of gastrointestinal lipase inhibitors
ATE450622T1 (de) Gene und proteine für verhinderung, vorhersage, prognose und therapie der herzgefäss-krankheit
WO2001031579A3 (en) Methods and devices for identifying patterns in biological patterns
IS1966B (is) Peptíð p277 hliðstæður og lyfjasamsetningar sem innihalda þær, til meðhöndlunar eða sjúkdómsgreiningar á sykursýki
WO2008053478A3 (en) Compositions and methods for inhibiting hiv-1 replication and integrase activity

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties